Cargando…

Immune-related genes and gene sets for predicting the response to anti-programmed death 1 therapy in patients with primary or metastatic non-small cell lung cancer

Although antibodies targeting the immune checkpoint protein programmed death-1 (PD-1) exert therapeutic effects in patients with primary or metastatic non-small cell lung cancer (NSCLC), the majority of patients exhibit partial or complete resistance to anti-PD1 treatment. Thus, the aim of the prese...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Bolin, Yang, Min, Li, Kang, Li, Jia, Xu, Li, Xu, Fang, Xu, Yan, Ren, Dandan, Zhang, Jiao, Liu, Liyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161458/ https://www.ncbi.nlm.nih.gov/pubmed/34084219 http://dx.doi.org/10.3892/ol.2021.12801

Ejemplares similares

The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study
por: Chen, Bolin, et al.
Publicado: (2022)

Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti–Programmed Cell Death 1 Immunotherapy
por: Xu, Jian-Ying, et al.
Publicado: (2022)

Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy
por: Jiang, Meilin, et al.
Publicado: (2020)

The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma
por: Lu, Jia, et al.
Publicado: (2022)

Rh‐endostatin plus camrelizumab and chemotherapy in first‐line treatment of advanced non‐small cell lung cancer: A multicenter retrospective study
por: Pu, Xingxiang, et al.
Publicado: (2022)

Adaptively Weighted and Robust Mathematical Programming for the Discovery of Driver Gene Sets in Cancers
por: Xu, Xiaolu, et al.
Publicado: (2019)

Influence factors of the survival in colorectal cancer patients with second primary malignancy after surgery: A SEER database analysis
por: Liu, Liyu, et al.
Publicado: (2023)

Identification of key genes of anti-programmed death ligand 1 for meningioma immunotherapy by bioinformatic analysis
por: Zhang, Lijian, et al.
Publicado: (2022)

Consistency Analysis of Programmed Death-Ligand 1 Expression between Primary and Metastatic Non-Small Cell Lung Cancer: A Retrospective Study
por: Luo, Luqiao, et al.
Publicado: (2020)

Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma
por: Gao, Yuan, et al.
Publicado: (2017)

Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody
por: Liu, Gang, et al.
Publicado: (2021)

Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
por: Iafolla, Marco A. J., et al.
Publicado: (2017)

Baseline HBV Loads Do Not Affect the Prognosis of Patients with Hepatocellular Carcinoma Receiving Anti-Programmed Cell Death-1 Immunotherapy
por: Sun, Xuqi, et al.
Publicado: (2020)

Efficacy and safety profile of combining programmed cell death‐1 (PD‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small cell lung cancer (NSCLC)
por: Xu, Ziyi, et al.
Publicado: (2021)

The efficacy of anti‐programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma
por: Ogata, Dai, et al.
Publicado: (2021)

Programmed death-ligand 1 expression discrepancy between primary tumor and metastatic lymph nodes in non-small cell lung cancer
por: Kian, Waleed, et al.
Publicado: (2020)

Identification of Potential Core Genes Between Primary and Metastatic Malignant Melanoma and Analysis of Their Immune Correlation
por: Jia, Cong-Li, et al.
Publicado: (2022)

Transcriptomic profiling identifies differentially expressed genes associated with programmed cell death of nucellar cells in Ginkgo biloba L.
por: Li, Dahui, et al.
Publicado: (2019)

Lymphocyte activation gene-3 is associated with programmed death-ligand 1 and programmed cell death protein 1 in small cell lung cancer
por: Sun, Hui, et al.
Publicado: (2021)

Genomic Landscape of Metastatic Lymph Nodes and Primary Tumors in Non-Small-Cell Lung Cancer
por: Chen, Bing, et al.
Publicado: (2022)

Comparison of Rearranged During Transfection (RET) Gene Rearrangements in Primary Versus Metastatic Non-Small Cell Lung Cancer (NSCLC)
por: Zhang, Quxia, et al.
Publicado: (2018)

Potential effective diagnostic biomarker in patients with primary and metastatic small intestinal neuroendocrine tumors
por: Chen, Jianxian, et al.
Publicado: (2023)

Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma
por: Nie, Run-Cong, et al.
Publicado: (2020)

Clinical Perspectives to Overcome Acquired Resistance to Anti–Programmed Death-1 and Anti–Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
por: Lee, Yong Jun, et al.
Publicado: (2021)

Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization
por: Kim, Hye Ryun, et al.
Publicado: (2017)

Identification of Differentially Expressed Genes in Metastatic and Non-Metastatic Nasopharyngeal Carcinoma Cells by Suppression Subtractive Hybridization
por: Yang, Xu-Yu, et al.
Publicado: (2005)

Expression of anti-metastatic gene nm23.
por: Hennessy, C., et al.
Publicado: (1991)

Training Set Selection for the Prediction of Essential Genes
por: Cheng, Jian, et al.
Publicado: (2014)

Adverse cardiac events in the treatment of non-small cell lung cancer with programmed death-1and programmed death-ligand 1 inhibitors: A protocol for systematic review and meta-analysis
por: Li, Honglin, et al.
Publicado: (2020)

The Molecular Evolution and Functional Divergence of Lamprey Programmed Cell Death Genes
por: Guan, Xin, et al.
Publicado: (2019)

Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer
por: Severson, Tesa, et al.
Publicado: (2022)

Identification of Keratinocyte Differentiation-Involved Genes for Metastatic Melanoma by Gene Expression Profiles
por: Li, Kezhu, et al.
Publicado: (2021)

Comparison of the c‐MET gene amplification between primary tumor and metastatic lymph nodes in non‐small cell lung cancer
por: Xu, Chun‐wei, et al.
Publicado: (2017)

Case Report: Tissue Origin Identification for Cancer of Unknown Primary: Gene Expression Profiling Approach
por: Pu, Xingxiang, et al.
Publicado: (2021)

Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients
por: Qiu, Lupeng, et al.
Publicado: (2020)

The incidence of pseudoprogressive disease associated with programmed cell death 1/programmed cell death ligand 1 inhibitors: A meta-analysis
por: Zhang, Jingyi, et al.
Publicado: (2021)

Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas
por: Wu, Kui, et al.
Publicado: (2015)

Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients
por: Li, Kang, et al.
Publicado: (2022)

Contributions of Gene Modules Regulated by Essential Noncoding RNA in Colon Adenocarcinoma Progression
por: Li, Chunhua, et al.
Publicado: (2020)

Gene Set Enrichment Analysis Detected Immune Cell-Related Pathways Associated with Primary Sclerosing Cholangitis
por: Luo, Pan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7714352j9ieoptet8d45h91fmv